International Life Sciences Awards 2019

GHP / International Life Sciences Awards 2019 17 , Nordic Captial Nordic Capital Acquires ArisGlobal, A Leading Global Provider Of Life Sciences Software As a leading healthcare and technology investor, Nordic Capital will further support and accelerate ArisGlobal’s growth. Nordic Capital Fund IX has announced an agreement to acquire US-headquartered ArisGlobal, a leading global provider of innovative SaaS software solutions, which are transforming the very way that most successful life sciences companies handle drug safety, clinical development, regulatory compliance, and medical affairs. Drawing on its deep understanding of both the healthcare and technology sectors, Nordic Capital will support ArisGlobal’s continued development. The founders of ArisGlobal will remain as minority shareholders. ArisGlobal is a visionary technology company that has successfully developed a next- generation platform that uses advanced cognitive computing and machine learning to automate all core functions of drug safety, regulatory compliance and medical affairs. Currently, more than 200 life sciences companies such as AstraZeneca, NovoNordisk, Merck and Novartis, CROs and government health authorities, as well as 40 of the top 50 global biopharmaceutical companies, rely on ArisGlobal’s solutions. Benefiting from deep expertise, longstanding customer relationships and a 30-year track record, ArisGlobal assists clients in maintaining regulatory compliance, managing and mitigating risk, and improving operational efficiency. ArisGlobal is headquartered in Miami, FL, USA, with regional offices in Europe, India, Japan and China. It has 1,200 employees globally and c. USD 100 million of annual revenues. In recent years, ArisGlobal has invested in transforming its traditional on-premise offering to a hosted solution sold through a SaaS model. “This transaction is representative of our rapid growth in the global life sciences industry, which is further proven by the adoption of our LifeSphere platform by the U.S. FDA. We look forward to partnering with Nordic Capital to leverage our common vision, values and combined talents to offer the most innovative technology platform to the life science industry. Nordic Capital has extensive experience in the pharma IT market from previous investments, and a proven track-record building strong teams which can further accelerate ArisGlobal’s growth. Nordic Capital also has a long track-record of partnerships with founding families and is well positioned to support our continued growth over the years to come,” says Deepak Abbhi, Founder and Chairman of the Board of ArisGlobal. “We are now embarking on a new chapter that will accelerate our ability to achieve our mission. Our unwavering focus on our customers’ needs will continue to be the core of who we are as a company. It drives the development of our LifeSphere platform. It fuels our passion for becoming the premier innovative technology company in the world. We share a closely aligned vision with Nordic Capital for the future of the industry and this partnership gives us immediate access to deep resources and expert guidance that will help us in our journey. I am more excited than ever about the future,” says Sankesh Abbhi, President and CEO of ArisGlobal. “This investment lies at the heart of Nordic Capital’s investment strategy as a leading healthcare and technology investor. We have followed the pharmacovigilance market very closely for over several years and now know the industry well. ArisGlobal has a top-quality management team and its success is based on its commitment to develop leading and innovative cloud-based software that help organisations maintain regulatory compliance, manage and mitigate risk, and improve operational efficiency. ArisGlobal’s SaaS native software is becoming the preferred choice for life sciences companies because it enables them to quickly implement cost-effective solutions for drug safety reporting, regulatory compliance, and medical affairs,” says Daniel Berglund, Principal at the Advisor to the Nordic Capital Funds. “The US is a key global market for healthcare companies and offers opportunities that are consistent with Nordic Capital’s investment strategy. ArisGlobal is a company that fits well within the portfolio and is well placed to achieve long term growth driven by favourable sector trends such as continued technological and scientific innovation, serving an attractive innovation driven customer base. We look forward to partnering with ArisGlobal where Nordic Capital can deploy its unique combination of capital and strong operational skills to accelerate growth and support positive transformative change.” says Dr Raj Shah, Partner, Co-Head of Healthcare at the Advisor to the Nordic Capital Funds.